Translational breast cancer research : a journal focusing on translational research in breast cancer最新文献

筛选
英文 中文
Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future? 早期乳腺癌省略前哨淋巴结活检:太大胆还是未来?
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-07-23 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-25-14
Jianli Zhao, Ziyue Zhou, Wei Zhang, Kai Chen
{"title":"Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future?","authors":"Jianli Zhao, Ziyue Zhou, Wei Zhang, Kai Chen","doi":"10.21037/tbcr-25-14","DOIUrl":"10.21037/tbcr-25-14","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"27"},"PeriodicalIF":1.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04. 在ASCENT-04中,抗体-药物偶联结合免疫治疗作为转移性三阴性乳腺癌的一线治疗方案的精确靶向细胞毒性
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-07-23 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-25-32
Li Bian, Shaohua Zhang, Man Li, Jin Yang, Yongmei Yin
{"title":"Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04.","authors":"Li Bian, Shaohua Zhang, Man Li, Jin Yang, Yongmei Yin","doi":"10.21037/tbcr-25-32","DOIUrl":"10.21037/tbcr-25-32","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"29"},"PeriodicalIF":1.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer. DESTINY-Breast09, her2阳性晚期乳腺癌一线治疗新突破。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-07-23 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-25-35
Jianbing Li, Chunfang Hao, Haibo Wang, Yueyin Pan, Zefei Jiang
{"title":"DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer.","authors":"Jianbing Li, Chunfang Hao, Haibo Wang, Yueyin Pan, Zefei Jiang","doi":"10.21037/tbcr-25-35","DOIUrl":"10.21037/tbcr-25-35","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"28"},"PeriodicalIF":1.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Key breast cancer highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 2025年美国临床肿瘤学会(ASCO)年会上乳腺癌的主要亮点。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-07-22 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-25-26
Janhavi Venkataraman, Kefah Mokbel
{"title":"Key breast cancer highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.","authors":"Janhavi Venkataraman, Kefah Mokbel","doi":"10.21037/tbcr-25-26","DOIUrl":"10.21037/tbcr-25-26","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"26"},"PeriodicalIF":1.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2. 靶向HER2的乳腺癌临床诊断与治疗的中国专家共识。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-07-22 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-25-34
Jianbin Li, Yueping Liu, Shu Wang, Shusen Wang, Shaohua Zhang, Man Li, Jin Yang, Xueli Mo, Min Yan, Cuizhi Geng, Feng Jin, Yongmei Yin, Jiong Wu, Erwei Song, Zefei Jiang
{"title":"Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2.","authors":"Jianbin Li, Yueping Liu, Shu Wang, Shusen Wang, Shaohua Zhang, Man Li, Jin Yang, Xueli Mo, Min Yan, Cuizhi Geng, Feng Jin, Yongmei Yin, Jiong Wu, Erwei Song, Zefei Jiang","doi":"10.21037/tbcr-25-34","DOIUrl":"10.21037/tbcr-25-34","url":null,"abstract":"<p><strong>Background: </strong>Human epidermal growth factor receptor 2 (HER2) is an important driver gene and prognostic indicator of breast cancer and also a key predictor of HER2-targeted therapies. Both the low expression and the positive expression of the HER2 protein are clinically significant for disease treatment and prognosis.</p><p><strong>Methods: </strong>(I) Establishment of expert group: the expert group consists of experts from departments such as medical oncology, breast surgery, and pathology; (II) literature search: mainly conducted in English databases (such as PubMed, Embase, and Cochrane Library) with a search cutoff date of June 1, 2025; (III) assessment of evidence quality and recommendation strength: evidence quality and recommendation opinions are graded based on the evidence category and recommendation level of the Chinese Society of Clinical Oncology (CSCO) guidelines.</p><p><strong>Results: </strong>The emerging anti-HER2 drugs have greatly changed the diagnosis and treatment modalities of breast cancer and dramatically improved the prognosis of patients with HER2 expression in breast cancer. To optimize the treatment, an update of expert consensus on breast cancer with HER2 expression was made to adjust the different recommendation levels from early stage to metastatic stage. In this consensus, we also talk about the importance of clinical research, real-world evidence, biosimilars and so on.</p><p><strong>Conclusions: </strong>The overarching goal of this consensus is to deliver individualized treatment strategies that not only prolong survival but also enhance quality of life, ensuring HER2-positive breast cancer patients receive the most advanced, patient-centered care available.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"21"},"PeriodicalIF":1.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses. 曲妥珠单抗德鲁西替康在不同免疫组织化学状态下重度预处理her2低转移性乳腺癌的实际疗效和安全性
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-07-18 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-25-8
Song Wu, Jianbin Li, Li Bian, Siyuan Zhang, Shaohua Zhang, Tao Wang, Zefei Jiang
{"title":"Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses.","authors":"Song Wu, Jianbin Li, Li Bian, Siyuan Zhang, Shaohua Zhang, Tao Wang, Zefei Jiang","doi":"10.21037/tbcr-25-8","DOIUrl":"10.21037/tbcr-25-8","url":null,"abstract":"<p><strong>Background: </strong>There are limited clinical data to compare the efficacy of trastuzumab deruxtecan (T-DXd) between the immunohistochemistry (IHC) 1+ and 2+ subgroups of human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (MBC). This study investigated the outcomes of T-DXd across distinct IHC statuses in HER2-low MBC.</p><p><strong>Methods: </strong>Patients with HER2-low MBC treated with T-DXd from June 2022 to December 2023 at The Fifth Medical Centre of Chinese PLA General Hospital were enrolled. The IHC status of patients was defined by the higher IHC score between the primary and metastatic lesions. The primary study endpoint was progression-free survival (PFS), and the secondary endpoint was safety.</p><p><strong>Results: </strong>Among the 70 patients, the IHC 1+ group comprised 37 patients, and the IHC 2+ group included 33 patients. Thirty-three (47.1%) patients had received ≥3 lines of chemotherapy before T-DXd treatment. The median initial T-DXd dose was 4.6 mg/kg [interquartile range (IQR): 3.7-5.3 mg/kg] every 3 weeks. A statistically significant difference in PFS was found between the IHC 1+ and 2+ groups in both univariate and multivariate analyses (median PFS: 3 <i>vs.</i> 5 months; adjusted hazard ratio: 0.51, 95% confidence interval: 0.28-0.95, P=0.03). The multivariate analysis also indicated that intensive prior chemotherapy and insufficient initial T-DXd doses might negatively impact the efficacy of T-DXd. The safety analysis showed similar profiles between the IHC 1+ and 2+ groups.</p><p><strong>Conclusions: </strong>In real-world treatment scenarios, HER2-low MBC patients with higher IHC scores are more likely to benefit from T-DXd, regardless of whether the scores are detected from primary or metastatic lesions.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"22"},"PeriodicalIF":1.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies. 转移性乳腺癌的精确治疗:基于分子改变疗法的现状。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-07-16 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-25-11
Hafez M A Abdullah, Suma Sri Chennapragada, Rohit Singh, Jehad M J Zeidalkilani, Meghana Kesireddy
{"title":"Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies.","authors":"Hafez M A Abdullah, Suma Sri Chennapragada, Rohit Singh, Jehad M J Zeidalkilani, Meghana Kesireddy","doi":"10.21037/tbcr-25-11","DOIUrl":"10.21037/tbcr-25-11","url":null,"abstract":"<p><p>Breast cancer is the most commonly diagnosed cancer in women globally and remains the leading cause of cancer-related death among women. De novo metastatic breast cancer accounts for 5-10% of annual diagnoses, and approximately 30% of women with early-stage disease will eventually experience metastatic recurrence. Median survival varies by tumor subtype: 64-68 months for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative cancers, 57-60 months for HER2-positive cancers, and around 13 months for triple-negative cancers. While current treatments-including chemotherapy, antibody-drug conjugates, endocrine therapy, HER2-targeted therapies, and immunotherapy-have significantly improved outcomes, resistance and disease progression remain ongoing challenges. Advances in next-generation sequencing (NGS) have enabled the identification of molecular alterations amenable to targeted therapy, underscoring the need for continued research into novel therapeutic targets. As more targeted agents become available and others are in development, staying informed about emerging targetable molecular alterations is increasingly essential. This review aims to summarize current data on targetable molecular alterations in metastatic breast cancer, focusing on available therapeutic options, key clinical trials, and practical insights for oncologists to support informed decision-making.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"24"},"PeriodicalIF":1.4,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodality evaluation and ultrasound-guided aspiration of a biopsy-proven inspissated clogged milk duct: a case report. 超声引导下活检证实的密集乳管阻塞的多模态评估和抽吸:1例报告。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-24-56
Kendal L Weger, Nicole P Sandhu, Mohammed Abdelwahed, Christine U Lee
{"title":"Multimodality evaluation and ultrasound-guided aspiration of a biopsy-proven inspissated clogged milk duct: a case report.","authors":"Kendal L Weger, Nicole P Sandhu, Mohammed Abdelwahed, Christine U Lee","doi":"10.21037/tbcr-24-56","DOIUrl":"10.21037/tbcr-24-56","url":null,"abstract":"<p><strong>Background: </strong>Despite the benefits of breastfeeding to both infant and mother, many mothers find breastfeeding difficult secondary to many complications such as pain, breast engorgement, mastitis, and clogged milk ducts. The latter is typically treated conservatively with techniques such as gentle massage, breast pumping, and compresses. When conservative therapies are unsuccessful, more invasive options are considered to ensure the continuation of breastfeeding.</p><p><strong>Case description: </strong>A 34-year-old lactating female presented with a 3-month history of worsening left breast and nipple pain radiating to the left upper outer quadrant, not relieved with conservative therapies. The physical exam revealed a small indentation and a small palpable nodule of the left nipple. There was no associated erythema or redness. Targeted ultrasound and subareolar magnification views revealed findings most consistent with a probably benign inspissated clogged milk duct. Given the patient's history, inability to express milk from the left breast, and plan to lactate for another year, ultrasound-guided aspiration was desired. Post-aspiration images demonstrated complete resolution of the nipple mass. Pathology revealed blood and proteinaceous material, in keeping with the diagnosis of inspissated clogged milk duct. Following the procedure, the patient's symptoms resolved completely.</p><p><strong>Conclusions: </strong>We present a case of irretractable milk duct plug treated with ultrasound-guided direct aspiration of the plug with complete resolution and minimal side effects to the patient.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"30"},"PeriodicalIF":1.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Escalation and optimisation of primary breast cancer treatment with antibody-drug conjugates. 抗体-药物偶联物治疗原发性乳腺癌的升级和优化。
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-06-18 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-25-2
Masakazu Toi
{"title":"Escalation and optimisation of primary breast cancer treatment with antibody-drug conjugates.","authors":"Masakazu Toi","doi":"10.21037/tbcr-25-2","DOIUrl":"10.21037/tbcr-25-2","url":null,"abstract":"<p><p>Antibody-drug conjugates (ADCs) have become the standard of care for metastatic advanced breast cancers, regardless of tumour subtype. Optimal positioning and treatment sequences are being studied, and many new therapies and combinations are also under development. Research into the application of ADC to early breast cancer is spreading. More than 10 clinical trials are being conducted regarding escalation and de-escalation of systemic treatment. In addition, in the sequence of neoadjuvant and adjuvant therapy, multiple key issues are investigated, such as effective sequences of treatments among ADC, cytotoxic chemotherapy, immunotherapy, and anti-human epidermal growth factor receptor 2 antibody therapy to improve treatment response, prognosis and quality of life (QOL). The postoperative activity of ADC with topoisomerase inhibitors for residual diseases is also being studied in post-neoadjuvant therapy settings. At the same time, many studies have focused on the appropriate timing of surgical therapy and response-guided approach. On the other hand, ADCs can cause serious side effects, although these are infrequent. Therefore, careful management is necessary during both pre-operative and post-operative adjuvant therapy. It is also crucial to focus on developing prognostic and predictive biomarkers to assess efficacy, alongside monitoring markers through translational research and image analysis. This review summarizes the development trends in both neoadjuvant and adjuvant settings, as well as recent data on ADCs for primary breast cancer, while addressing unresolved clinical questions. It discusses the escalation and optimization of treatment for primary breast cancer using ADCs, along with the relevant challenges and perspectives.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"23"},"PeriodicalIF":1.4,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab. 曲妥珠单抗德鲁德替康治疗低HR+/ her2乳腺癌骨转移患者:地诺单抗增强疗效
IF 1.4
Translational breast cancer research : a journal focusing on translational research in breast cancer Pub Date : 2025-05-06 eCollection Date: 2025-01-01 DOI: 10.21037/tbcr-24-50
Azzurra Irelli, Leonardo Valerio Patruno, Katia Cannita
{"title":"Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab.","authors":"Azzurra Irelli, Leonardo Valerio Patruno, Katia Cannita","doi":"10.21037/tbcr-24-50","DOIUrl":"10.21037/tbcr-24-50","url":null,"abstract":"<p><p>Approximately 60% of human epidermal growth factor receptor 2-negative (HER2-) breast cancers (BCs) are HER2-low [immunohistochemistry (IHC) 1+ or 2+/in situ hybridization (ISH)-]. The proportion of BC patients with hormone receptor-positive (HR+)/HER2- are more likely to metastasize to bone. The phase 3 Destiny-Breast04 study led to the approval of the antibody drug conjugate trastuzumab deruxtecan (T-DXd) in HER2-low patients, even HR+, after lines of endocrine therapy and one line of chemotherapy. Recently, the Destiny-Breast06 study showed a progression-free survival advantage of T-DXd also in first-line. T-DXd has an immunological effect as it can produce antibody-dependent cellular cytotoxicity-like effects by recruiting dendritic cells and CD8+ T cells. This immunological effect can be enhanced using immune checkpoint inhibitors but also the anti-RANK-ligand (RANKL) antibody denosumab, which can be used for the prevention of skeletal-related events (SREs). RANK modulates HER2-driven carcinogenesis because both RANK and HER2 activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Thus, increased RANK signaling may contribute to the development of resistance to anti-HER2 therapy through NF-κB activation. It remains to be seen whether patients with HER2-positive or HER2-low BC that express RANK may benefit from concomitant HER2 and RANK inhibition therapy. Except for the Destiny-Breast06 study, which included only 3% of enrolled patients with exclusive bone metastases, we have no clinical data on the efficacy of T-DXd in bone metastases and on the concomitant use of T-DXd and denosumab, although the biological rationale for the increased efficacy of the combination is strong.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"25"},"PeriodicalIF":1.4,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信